NeuroOne Medical Technologies (NMTC) AI Stock Analysis

• Market Cap: $45.32M
• Dividend Yield: N/A
• Average Volume (3M): 532.45K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.76
• Revenue Growth: 250.35%
• EPS Growth: 83.06%
• Country: US
• Employees: 17
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.05
• Shares Outstanding: 50,413,147
• 10 Day Avg. Volume: 702,340
• 30 Day Avg. Volume: 532,447
• PEG Ratio: 0.12
• Price to Book (P/B): 5.04
• Price to Sales (P/S): 3.92
• P/FCF Ratio: -12.22
• Enterprise Value/Market Cap: 0.65
• Enterprise Value/Revenue: 3.22
• Enterprise Value/Gross Profit: 5.69
• Enterprise Value/Ebitda: -9.72
• 1Y Price Target: $3.00
• Price Target Upside: 322.54% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 50 Neutral
• Price Target: $0.98 ▲(38.03% Upside)

The score is held down primarily by weak financial quality (ongoing losses and negative operating/free cash flow) despite strong top-line growth. Technicals are supportive but appear overextended, while the latest earnings call was a meaningful positive (sales acceleration, margin improvement, FDA clearance, and stronger liquidity) that partially offsets the financial and compliance risks.

Positive Factors

Revenue Growth

Sustained, large percentage increases in product revenue demonstrate real commercialization traction and accelerating market adoption. Over 2–6 months this supports scaling opportunities, strengthens distributor negotiation leverage (e.g., Zimmer Biomet partnership) and validates product-market fit.

Improving Gross Margins

Material gross margin improvement indicates better unit economics and potential scalability as volumes rise. Higher product margins plus reduced operating expenses suggest structural progress toward sustainable profitability as sales scale and manufacturing or pricing efficiency persists.

Regulatory and Pipeline Progress

Achieving FDA 510(k) clearance reduces a major commercialization barrier and legitimizes the platform for clinicians. Ongoing development of spinal cord and basivertebral programs diversifies the pipeline, expanding addressable markets and lowering single-product dependency over the medium term.

Negative Factors

Ongoing Net Losses

Despite improvement, continued net losses constrain retained earnings and require external funding until sustained profitability is reached. Persistent losses increase financing frequency risk, can dilute shareholders, and place long-term pressure on management to deliver cash-positive operations.

Negative Cash Flow

Negative operating and free cash flows indicate the business currently burns cash despite revenue growth. Over months this elevates reliance on capital raises to fund growth, limits reinvestment capacity, and heightens execution risk if fundraising windows narrow or terms become dilutive.

Nasdaq Compliance / Delisting Risk

A formal compliance extension signals governance and market-access risk; potential delisting would materially hinder capital raising, institutional participation, and commercial credibility. Combined with limited cash runway, this creates a persistent operational and strategic distraction for management.

NeuroOne Medical Technologies Business Overview & Revenue Model

Company Description

NeuroOne Medical Technologies (NMTC) is a medical device company focused on developing innovative solutions for neurological disorders, specifically targeting conditions such as epilepsy and chronic pain. The company operates within the healthcare sector, primarily specializing in advanced electrode technology and implantable devices designed for brain monitoring and stimulation. NMTC's core products include its ultra-thin and flexible electrode arrays, which are intended to improve the treatment outcomes for patients undergoing neurological procedures.

How the Company Makes Money

NeuroOne Medical Technologies generates revenue primarily through the sale of its medical devices, particularly its electrode technology used in neurosurgical procedures. The company may also earn income from licensing agreements, collaborations with larger medical device firms, and partnerships with research institutions. Additionally, NMTC could benefit from reimbursement models established by healthcare providers for the use of its products in clinical settings. Significant partnerships with hospitals and neurology clinics could further enhance its market reach and contribute to consistent revenue generation.

NeuroOne Medical Technologies Financial Statement Overview

Summary

NeuroOne Medical Technologies is experiencing strong revenue growth, but profitability and cash flow remain significant challenges. The balance sheet is stable with low leverage, but the company needs to improve its operational efficiency to enhance profitability and cash flow.

Income Statement

The company has shown significant revenue growth of 37.24% in the latest year, indicating a positive trajectory. However, profitability remains a concern with negative net profit and EBIT margins, reflecting ongoing operational challenges.

Balance Sheet

The balance sheet shows a low debt-to-equity ratio, suggesting conservative leverage. However, the negative return on equity indicates that the company is not generating profits from its equity base, which is a concern for investors.

Cash Flow

The company has negative operating and free cash flows, which have shown a decline in growth. The cash flow to net income ratios are unfavorable, indicating cash flow challenges despite revenue growth.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	9.10M	12.10M	3.45M	1.95M	171.17K	178.15K
Gross Profit	5.14M	8.14M	1.08M	456.52K	-70.79K	-97.75K
EBITDA	-3.01M	-3.01M	-11.84M	-11.76M	-9.91M	-9.80M
Net Income	-3.61M	-3.61M	-12.32M	-11.86M	-10.00M	-9.95M
Balance Sheet
Total Assets	10.79M	10.79M	5.37M	8.10M	12.82M	7.94M
Cash, Cash Equivalents and Short-Term Investments	6.57M	6.57M	1.46M	5.32M	11.14M	6.90M
Total Debt	266.81K	266.81K	260.16K	184.40K	202.90K	315.67K
Total Liabilities	3.71M	3.71M	4.55M	1.85M	3.22M	1.38M
Stockholders Equity	7.07M	7.07M	822.01K	6.25M	9.60M	6.55M
Cash Flow
Free Cash Flow	-2.92M	-2.92M	-11.13M	-13.27M	-7.79M	-8.67M
Operating Cash Flow	-2.84M	-2.84M	-11.01M	-12.89M	-7.52M	-8.60M
Investing Cash Flow	-81.74K	-81.74K	-120.20K	2.65M	-3.24M	-67.08K
Financing Cash Flow	141.42K	141.42K	7.27M	7.40M	12.02M	11.53M

NeuroOne Medical Technologies Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.71
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NMTC, the sentiment is Positive. The current price of 0.71 is below the 20-day moving average (MA) of 0.82, below the 50-day MA of 0.73, and below the 200-day MA of 0.74, indicating a bullish trend. The MACD of 0.05 indicates Negative momentum. The RSI at 61.26 is Neutral, neither overbought nor oversold. The STOCH value of 38.32 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NMTC.

NeuroOne Medical Technologies Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SRTS	65 Neutral	$81.47M	―	-5.71%	―	-13.79%	-132.21%
ECOR	52 Neutral	$54.29M	-3.98	-337.84%	―	27.90%	1.62%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
NMTC	50 Neutral	$45.32M	-11.51	-91.34%	―	250.35%	83.06%
RBOT	45 Neutral	$20.36M	-0.29	-148.93%	―	―	15.03%
IINN	42 Neutral	$31.79M	-1.90	―	―	―	―

NeuroOne Medical Technologies Corporate Events

NeuroOne Appoints Jason R. Mills to Board

On December 18, 2025, NeuroOne’s board expanded from four to five members and appointed Jason R. Mills as a Class I director, with his committee roles on the Compensation and Nominating & Corporate Governance Committees effective January 1, 2025, a move publicly announced on December 22, 2025. Mills, currently Executive Vice President of Strategy at Penumbra and a former award-winning med-tech equity research analyst, brings deep industry, strategic and capital markets experience that NeuroOne’s leadership believes will support its clinical and corporate objectives and help broaden its reach as it seeks to advance and commercialize its neurological disorder treatment technologies; on the same day, the company also posted an updated corporate presentation to its investor website to support ongoing communications with the market.

The most recent analyst rating on (NMTC) stock is a Hold with a $0.68 price target. To see the full list of analyst forecasts on NeuroOne Medical Technologies stock, see the NMTC Stock Forecast page.

NeuroOne Gets Nasdaq Extension for Compliance

On November 4, 2025, NeuroOne Medical Technologies received a 180-day extension from Nasdaq to comply with the minimum bid price requirement of $1.00 per share for its common stock to remain listed. The extension allows the company until May 4, 2026, to address the compliance issue, with no immediate impact on its current Nasdaq listing. Failure to meet the requirement by the deadline could lead to delisting, although the company plans to monitor and address the issue within the given timeframe.

The most recent analyst rating on (NMTC) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on NeuroOne Medical Technologies stock, see the NMTC Stock Forecast page.